ADVERTISEMENT
LIVE DESK·Global markets desk·Last updated 14s ago
ADVERTISEMENT
Markets/EquitiesArticle

Onto Innovation director sells $302,300 in shares under pre-arranged plan

Susan D. Lynch disposed of 1,000 common shares at $302.30 each, leaving her with 2,684 shares. The sale followed a 169% annual gain and Q2 results that beat earnings and revenue forecasts.

PA
Priya Anand · Equities & Earnings Desk · 31 Aug 2026 · 00:02 · 1 min read
Share
Onto Innovation director sells $302,300 in shares under pre-arranged plan

A director of Onto Innovation Inc. (NASDAQ: ONTO) sold 1,000 common shares on August 21, 2026, for a total of $302,300, according to a regulatory filing. The transaction was executed at $302.30 per share under a pre-arranged Rule 10b5-1 trading plan adopted on May 22, 2026. After the disposal, Susan D. Lynch retains 2,684 shares in the company.

The disposal follows a 169% increase in Onto Innovation’s stock over the past year, though shares retreated 7.6% in the week prior to the sale. The company reported second-quarter earnings of $1.93 per share, exceeding Wall Street expectations of $1.69, and revenue of $343.1 million, above analyst projections of $325.25 million. Revenue rose 18% sequentially and 35% year-over-year, setting a new company record.

Onto Innovation also raised its guidance for the second half of 2026. Analysts at Goldman Sachs initiated coverage with a buy rating and a $400 price target, citing artificial intelligence demand as a key driver for the company’s inspection and metrology equipment used in semiconductor manufacturing. InvestingPro analysis had previously flagged the stock as overvalued relative to its fair value estimate.

This article was produced with AI assistance and edited by a Finance Review Daily journalist.
ADVERTISEMENT
Novara — A Smarter Way to Access Global Markets
Share this story
PA
Written by
Priya Anand
Equities & Earnings Desk

Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.

More from Priya Anand →
ADVERTISEMENT
ADVERTISEMENT